# Mettler Toledo International Inc/: Form 10-Q for the period ended Sep 30, 2020

- Company: [Mettler Toledo International Inc/](/companies/mtd.md) (CIK 1037646)
- Form: 10-Q
- Filed: 2020-11-06
- Accepted by EDGAR: Nov 6, 2020, 09:16 ET
- Period: 2020-09-30
- Accession: 0001037646-20-000030
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1037646/000103764620000030/mtd-20200930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1037646/000103764620000030/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-01 to 2020-09-30 | $807.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-09-30 | $2.15bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2020-07-01 to 2020-09-30 | $469.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-09-30 | $1.24bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-07-01 to 2020-09-30 | $34.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-01-01 to 2020-09-30 | $100.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-07-01 to 2020-09-30 | $205.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-30 | $593.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2020-07-01 to 2020-09-30 | $9.3m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-30 | $29.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-07-01 to 2020-09-30 | $44.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-30 | $93.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-01 to 2020-09-30 | $161.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-30 | $386.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-01 to 2020-09-30 | $6.68 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-30 | $15.92 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-01 to 2020-09-30 | $6.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-30 | $16.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-01 to 2020-09-30 | 24,225,204 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-30 | 24,272,354 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-30 | $473.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-30 | $57.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2020-01-01 to 2020-09-30 | $400.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-09-30 | $153.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-30 | $1.05bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-30 | $2.77bn | us-gaap:Assets |
| Current liabilities | at 2020-09-30 | $764.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-30 | $2.32bn | us-gaap:Liabilities |
| Long-term debt | at 2020-09-30 | $1.17bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-09-30 | $55.1m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2020-09-30 | $443.1m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2020-09-30 | 23,794,563 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 36,551 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.*

### General

Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year ending December 31, 2020.

Changes in local currency exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.

We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.

### COVID-19

The 2019 Coronavirus (COVID-19) pandemic has resulted in millions of confirmed cases throughout the world and in all countries where we conduct business. The outbreak has caused many governments to implement stay-at-home orders, quarantines and significant restrictions on travel. Several governments have also implemented work restrictions that prohibit many employees from going to their customary work locations and which require these employees to work remotely if possible. The quarantines, travel bans, work and other restrictions were initially put in place on a national level in China in January 2020, and with the global spread of the virus, subsequently adopted in other countries and regions during the first quarter of 2020 with many restrictions commencing in Asia Pacific, Europe, North America, and South America. These restrictions continue to change as COVID-19 evolves in each country and region.

The health and safety of our employees and business partners has been our highest priority throughout the COVID-19 pandemic, and we have implemented several preventative and protective measures relating to social distancing, hygiene, health monitoring, personal protective equipment, split shifts and remote work. We have also implemented business continuity plans and have been able to continue to support our customers with their essential businesses such as in life sciences, food manufacturing, chemicals (e.g. sanitizers, disinfectants, soaps etc.), food retail and transportation and logistics. Our production and logistics facilities are currently operational, and our office-based employees have been able to work remotely in adherence to applicable jurisdictional stay-at-home orders. Our supply chain is currently continuing with minimal interruption, and we generally maintain adequate product inventory levels and safety stock for certain components. We quickly adapted to leverage our digital and remote sales and service capabilities, while also meeting delivery requirements with our global supply chain. Our service organization also continues to provide on-site and remote customer support to facilitate uptime, productivity and regulatory compliance.

We have also implemented various temporary cost containment measures related to workforce management and discretionary spending. Our workforce management measures primarily include reduced work hours, salary freezes, and voluntary senior leadership salary reductions.

We maintain adequate liquidity consisting of approximately $700.7 million of additional borrowings available under our Credit Agreement, and $153.7 million of cash and cash equivalents as of September 30, 2020.

As further described in the Risk Factors section of this Form 10-Q, COVID-19 presents several risks to our business. For example, businesses can be shutdown, supply chains can be interrupted, slowed, or rendered inoperable, and individuals can become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. COVID-19 also interferes with general commercial activity related to our supply chain and customer base. In addition, it is expected that COVID-19 will negatively affect the global economy and our customers' businesses, which will likely result in delayed or reduced purchases from us. Some customers may also have difficulty meeting their payment obligations to us, resulting in late payments or an inability of some customers to make payments at all.

During the nine months ended September 30, 2020, COVID-19 had a negative impact on our business, primarily related to reduced customer demand in all regions. We remain cautious as uncertainties related to COVID-19 and the resulting impact to the economy continues in most regions of the world and market conditions may also change quickly. With the global spread of the virus and related negative impact to the global economy, we may experience reduced global sales volume due to lower customer demand in future quarters. The longer-term effects on our business will be impacted by the global economy and any recession implications in different regions of the world. While it is extremely difficult to estimate the extent and duration of any COVID-19 implications, the effects on our business, results of operations and financial condition could be material.

### Results of Operations – Consolidated

The following tables set forth certain items from our interim consolidated statements of operations for the three and nine month periods ended September 30, 2020 and 2019 (amounts in thousands).

|  | Three months ended September 30, 2020 (unaudited)% |  | 2019 (unaudited)% |  | Nine months ended September 30, 2020 (unaudited)% |  | 2019 (unaudited)% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | $807,357 | 100.0 | $753,866 | 100.0 | $2,147,192 | 100.0 | $2,164,684 | 100.0 |
| Cost of sales | 337,749 | 41.8 | 318,810 | 42.3 | 905,205 | 42.2 | 921,771 | 42.6 |
| Gross profit | 469,608 | 58.2 | 435,056 | 57.7 | 1,241,987 | 57.8 | 1,242,913 | 57.4 |
| Research and development | 34,656 | 4.3 | 36,015 | 4.8 | 100,236 | 4.7 | 108,650 | 5.0 |
| Selling, general and administrative | 204,974 | 25.4 | 202,826 | 26.9 | 593,852 | 27.7 | 612,466 | 28.3 |
| Amortization | 14,121 | 1.7 | 12,329 | 1.6 | 42,008 | 2.0 | 36,877 | 1.7 |
| Interest expense | 9,310 | 1.2 | 9,800 | 1.3 | 29,111 | 1.3 | 27,776 | 1.3 |
| Restructuring charges | 4,570 | 0.6 | 6,732 | 0.9 | 7,335 | 0.3 | 11,146 | 0.5 |
| Other income, net | (3,832) | (0.5) | (2,005) | (0.3) | (10,118) | (0.5) | (4,253) | (0.2) |
| Earnings before taxes | 205,809 | 25.5 | 169,359 | 22.5 | 479,563 | 22.3 | 450,251 | 20.8 |
| Provision for taxes | 44,042 | 5.5 | 39,964 | 5.3 | 93,119 | 4.3 | 81,891 | 3.8 |
| Net earnings | $161,767 | 20.0 | $129,395 | 17.2 | $386,444 | 18.0 | $368,360 | 17.0 |

#### Net sales

Net sales were $807.4 million and $753.9 million for the three months ended September 30, 2020, and 2019, respectively, and $2.1 billion and $2.2 billion for the nine months ended September 30, 2020 and 2019, respectively. This represents an increase of 7% and a decrease of 1% in U.S. dollars for the three and nine months ended September 30, 2020, respectively. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 6% and were flat for the three and nine months ended September 30, 2020, respectively. Net sales for the nine months ended September 30, 2020 were negatively impacted by the COVID-19 pandemic and related reduction in global customer demand on our operations. Net sales for the three months ended September 30, 2020 reflected improved customer demand in most businesses and regions with particularly strong growth in China and our laboratory-related products. While we saw increased business activity during the third quarter of 2020, we remain cautious as uncertainties relating to COVID-19 and the global economy continue and market conditions may change quickly. Net sales in local currencies may be adversely affected in future quarters by the COVID-19 pandemic related to unfavorable economic conditions and reduced customer demand.

Net sales by geographic destination for the three months ended September 30, 2020 in U.S. dollars increased in the Americas 2%, in Europe 9% and in Asia/Rest of World 11%, and in local currencies increased in the Americas 3%, in Europe 4% and in Asia/Rest of World 10%. Our net sales by geographic destination for the nine months ended September 30, 2020 in U.S. dollars decreased in both the Americas and in Europe 1%, while Asia/Rest of World was flat. Net sales by geographic destination for the nine months ended September 30, 2020 in local currencies decreased in the Americas 1%, in Europe 2% and increased in Asia/Rest of World 1%. Net sales in Asia/Rest of World in local currency for the three months ended September 30, 2020 includes local currency growth in China of 17% that benefited from increased customer demand. A discussion of sales by operating segment is included below.

As described in Note 19 to our consolidated financial statements for the year ended December 31, 2019, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.

Net sales of products increased 7% in U.S. dollars and 6% in local currencies for the three months ended September 30, 2020 and decreased 1% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Service revenue (including spare parts) increased by 6% in U.S. dollars and 4% in local currencies for the three months ended September 30, 2020 and increased 1% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019.

Net sales of our laboratory products and services, which represented approximately 54% of our total net sales, increased 11% in U.S. dollars and 9% in local currencies for the three months ended September 30, 2020, and increased 2% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020. The local currency increase in net sales of our laboratory-related products for the three months ended September 30, 2020 includes growth in most product categories, with excellent results in pipettes, as well as strong growth in automated chemistry and process analytics. The local currency increase in net sales of our laboratory-related products for the nine months ended September 30, 2020 includes strong growth in pipettes, automated chemistry and process analytics, offset in part by declines in other product categories.

Net sales of our industrial products and services, which represented approximately 40% of our total net sales increased, 2% in U.S. dollars and 1% in local currencies for the three months ended September 30, 2020, and decreased 3% in U.S. dollars and 2% in local currencies for the nine months ended September 30, 2020. The local currency increase in net sales of our industrial-related products for the three months ended September 30, 2020 includes strong growth in core industrial products, offset in part by a decline in product inspection. Core industrial growth included particularly strong growth in China. The local currency decrease in net sales of our industrial-related products for the nine months ended September 30, 2020 includes a decline in product inspection, offset in part by modest growth in core industrial products.

Net sales in our food retailing products and services, which represented approximately 6% of our total net sales, increased 8% in U.S. dollars and 5% in local currencies for the three months ended September 30, 2020, and decreased 7% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020. The local currency increase in food retailing for the three months ended September 30, 2020 is primarily due to improved project activity in Europe and the Americas. The decline in food retailing for the nine months ended September 30, 2020 is primarily due to challenging market conditions.

#### Gross profit

Gross profit as a percentage of net sales was 58.2% and 57.7% for the three months ended September 30, 2020 and 2019, respectively and 57.8% and 57.4% for the nine months ended September 30, 2020 and 2019, respectively.

Gross profit as a percentage of net sales for products was 59.7% and 60.2% for the three months ended September 30, 2020 and 2019, respectively, and 60.0% for both the nine months ended September 30, 2020 and 2019.

Gross profit as a percentage of net sales for services (including spare parts) was 52.7% and 48.9% for the three months ended September 30, 2020 and 2019, respectively, and 50.5% and 48.5% for the nine months ended September 30, 2020 and 2019, respectively.

The increase in gross profit as a percentage of net sales for the three and nine months ended September 30, 2020 primarily reflects favorable price realization, benefits from temporary cost savings measures and material cost reductions, offset in part by higher transportation costs and unfavorable business mix. Gross profit for the three month period also benefited from improved sales volume.

#### Research and development and selling, general and administrative expenses

Research and development expenses as a percentage of net sales was 4.3% and 4.8% for the three months ended September 30, 2020 and 2019, respectively, and was 4.7% and 5.0% for the nine months ended September 30, 2020 and 2019, respectively. Research and development expenses decreased 4% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2020, and decreased 8% in U.S. dollars and 9% in local currencies for the nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The decrease relates to the timing of project activity and benefits from our temporary cost savings measures.

Selling, general and administrative expenses as a percentage of net sales were 25.4% and 26.9% for the three months ended September 30, 2020 and 2019, and was 27.7% and 28.3% for the nine months ended September 30, 2020 and 2019, respectively. Selling, general and administrative expenses increased 1% in U.S. dollars and decreased 1% in local currencies for the three months ended September 30, 2020, and decreased 3% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020. The local currency decrease includes benefits from our temporary and ongoing cost savings initiatives.

#### Amortization, interest expense, other charges (income), net and taxes

Amortization expense was $14.1 million and $12.3 million for the three months ended September 30, 2020 and 2019, respectively, and $42.0 million and $36.9 million for the nine months ended September 30, 2020 and 2019, respectively.

Interest expense was $9.3 million and $9.8 million for the three months ended September 30, 2020 and 2019, respectively, and $29.1 million and $27.8 million for the nine months ended September 30, 2020 and 2019, respectively.

Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and hedging activities, interest income and other items. Non-service pension benefits was $3.1 million and $1.2 million for the three months ended September 30, 2020 and 2019, respectively, and $9.0 million and $3.5 million and for the nine months ended September 30, 2020 and 2019, respectively.

Our reported tax rate was 21.4% and 23.6% during the three months ended September 30, 2020 and 2019, respectively, and 19.4% and 18.2% during the nine months ended September 30, 2020 and 2019, respectively. The provision for taxes is based upon using our projected annual effective tax rate of 20.5% and 20% before non-recurring discrete tax items for the three and nine months ended September 30, 2020 and 2019, respectively. The difference between our projected annual effective tax rate and the reported tax rate is related to the timing of excess tax benefits associated with stock option exercises.

### Results of Operations – by Operating Segment

The following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 19 to our consolidated financial statements for the year ended December 31, 2019.

#### U.S. Operations (amounts in thousands)

|  | Three months ended September 30, |  | Nine months ended September 30, |  |
| --- | ---: | ---: | ---: | ---: |
|  | 2020 | 2019% | 2020 | 2019% |
| Total net sales | $309,805 | $297,113 4% | $854,457 | $852,369 —% |
| Net sales to external customers | $278,948 | $269,038 4% | $769,696 | $771,578 —% |
| Segment profit | $65,493 | $54,628 20% | $163,012 | $146,599 11% |

Total net sales and net sales to external customers both increased 4% for the three months ended September 30, 2020 compared with the corresponding period in 2019. Total net sales and net sales to external customers were both flat for the nine months ended September 30, 2020 compared with the corresponding period in 2019. Net sales to external customers for the three months ended September 30, 2020 includes particularly strong growth in pipettes, as well as automated chemistry and process analytics, offset in part by a decline in product inspection. Net sales to external customers for the nine months ended September 30, 2020 includes strong growth in pipettes, transportation and logistics, and automated chemistry, offset by declines in most product categories reflecting reduced customer demand as a result of COVID-19.

Segment profit increased $10.9 million and $16.4 million for the three and nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. Segment profit during the three and nine months ended September 30, 2020 includes benefits from our temporary cost savings measures and margin expansion initiatives. Segment profit during the three months ended September 30, 2020 also includes benefits from our increased net sales volume.

#### Swiss Operations (amounts in thousands)

|  | Three months ended September 30, 2020 | 2019 | %1) | Nine months ended September 30, 2020 | 2019 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $206,183 | $194,151 | 6% | $562,364 | $564,748 | —% |
| Net sales to external customers | $38,848 | $33,415 | 16% | $99,693 | $98,350 | 1% |
| Segment profit | $61,902 | $54,226 | 14% | $164,060 | $156,361 | 5% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 6% in U.S. dollars and were flat in local currency for the three months ended September 30, 2020, and were flat in U.S. dollars and decreased 5% in local currency for the nine months ended September 30, 2020 compared to the corresponding periods in 2019. Net sales to external customers increased 16% in U.S. dollars and 11% in local currency for the three months ended September 30, 2020 and increased 1% in U.S. dollars and decreased 2% in local currency for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. The increase in local currency net sales to external customers for the three months ended

September 30, 2020 includes strong growth in laboratory-related products, especially process analytics, pipettes and automated chemistry. Net sales to external customers for the nine months ended September 30, 2020 includes declines in most products related to lower customer demand as a result of COVID-19, offset in part by strong growth in automated chemistry, product inspection and pipettes.

Segment profit increased $7.7 million for both the three and nine month periods ended September 30, 2020, compared to the corresponding periods in 2019. Segment profit during the nine months ended September 30, 2020 includes benefits from our temporary cost savings measures and the timing of research and development activity, offset in part by unfavorable currency translation. Segment profit during the three months ended September 30, 2020 also includes benefits from our increased sales volume.

#### Western European Operations (amounts in thousands)

|  | Three months ended September 30, 2020 | 2019 | %1) | Nine months ended September 30, 2020 | 2019 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $219,760 | $211,446 | 4% | $603,549 | $624,290 | (3)% |
| Net sales to external customers | $177,630 | $168,652 | 5% | $480,006 | $498,240 | (4)% |
| Segment profit | $36,954 | $29,888 | 24% | $91,406 | $77,842 | 17% |

1\) Represents U.S. dollar growth (decline) for net sales and segment profit.

Total net sales increased 4% in U.S. dollars and decreased 1% in local currencies for the three months ended September 30, 2020 and decreased 3% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers increased 5% in U.S. dollars and were flat in local currencies for the three months ended September 30, 2020, and decreased 4% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers for the three months ended September 30, 2020 includes strong growth in laboratory-related products, especially pipettes, and food retail, offset in part by a decline in product inspection. Net sales to external customers for the nine months ended September 30, 2020 includes declines in most product categories related to lower customer demand as a result of COVID-19, offset in part by strong growth in pipettes.

Segment profit increased $7.1 million and $13.6 million for the three and nine month periods ended September 30, 2020, respectively, compared to the corresponding periods in 2019. Segment profit increased during the three and nine months ended September 30, 2020 primarily due to benefits from our temporary cost savings measures and margin expansion initiatives and timing of research and development project activity. Segment profit for the three months ended September 30, 2020 also includes benefits from our increased net sales volume.

#### Chinese Operations (amounts in thousands)

|  | Three months ended September 30, 2020 | 2019 | %1) | Nine months ended September 30, 2020 | 2019 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $219,545 | $203,002 | 8% | $555,532 | $570,608 | (3)% |
| Net sales to external customers | $165,231 | $142,292 | 16% | $406,738 | $400,473 | 2% |
| Segment profit | $81,055 | $72,745 | 11% | $190,560 | $197,718 | (4)% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales increased 8% in U.S. dollars and 7% in local currency for the three months ended September 30, 2020 and decreased 3% in U.S. dollars and 1% in local currency for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers increased 16% in U.S. dollars and 15% in local currency by origin for the three months ended September 30, 2020 and increased 2% in U.S. dollars and 3% in local currency during the nine months ended September 30, 2020, compared to the corresponding periods in 2019.

The increase in local currency net sales to external customers during the three months ended September 30, 2020 reflects strong growth in industrial and laboratory-related products that benefited from improved customer demand. However, uncertainty remains and market conditions may change quickly.

Segment profit increased $8.3 million and decreased $7.2 million for the three and nine month periods ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The decrease in segment profit for the nine months ended September 30, 2020 primarily reflects the decline in total net sales as well as unfavorable foreign currency translation, offset in part by our temporary cost savings measures. Segment profit for the three months ended September 30, 2020 also includes benefits from our increased net sales volume.

#### Other (amounts in thousands)

|  | Three months ended September 30, 2020 | 2019 | %1) | Nine months ended September 30, 2020 | 2019 | %1) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total net sales | $148,209 | $141,982 | 4% | $394,340 | $400,151 | (1)% |
| Net sales to external customers | $146,700 | $140,469 | 4% | $391,059 | $396,043 | (1)% |
| Segment profit | $23,554 | $17,938 | 31% | $47,702 | $45,425 | 5% |

1\) Represents U.S. dollar growth for net sales and segment profit.

Total net sales and net sales to external customers increased 4% in U.S. dollars and 5% in local currencies for the three months ended September 30, 2020, compared to corresponding periods in 2019. Total net sales decreased 1% in U.S. dollars and were flat in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers decreased 1% in U.S. dollars and increased 1% in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. The increase in net sales to external customers for the three months ended September 30, 2020 includes solid growth in most product categories. The increase in net sales to external customers for the nine months ended September 30, 2020 includes growth in laboratory-related products offset in part by a decline in industrial-related products due to reduced customer demand related to COVID-19.

Segment profit increased $5.6 million and $2.3 million for the three and nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The increase in segment profit for the nine months ended September 30, 2020 primarily reflects benefits from our temporary cost saving measures, offset in part by unfavorable foreign currency translation. The increase in segment profit for the three months ended September 30, 2020 also includes benefits from our higher net sales volume.

### Liquidity and Capital Resources

Liquidity is our ability to generate sufficient cash to meet our obligations and commitments. Sources of liquidity includes, cash flows from operating activities, available borrowings under our Credit Agreement, the ability to obtain appropriate financing and our cash and cash equivalent balances. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.

Cash provided by operating activities totaled $473.8 million during the nine months ended September 30, 2020, compared to $401.7 million in the corresponding period in 2019. The increase for the nine months ended September 30, 2020 benefited from favorable working capital including strong cash collections and higher net earnings as compared to the prior year period.

Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $57.4 million for the nine months ended September 30, 2020 compared to $71.6 million in the corresponding period in 2019. We expect to make net investments in new or expanded manufacturing facilities of $10 million to $15 million over the next two years.

#### Senior Notes and Credit Facility Agreement

Our debt consisted of the following at September 30, 2020:

|  | U.S. Dollar | Other Principal Trading Currencies | Total |
| --- | ---: | ---: | ---: |
| 3.67% $50 million ten-year Senior Notes due December 17, 2022 | $50,000 | $— | $50,000 |
| 4.10% $50 million ten-year Senior Notes due September 19, 2023 | 50,000 | — | 50,000 |
| 3.84% $125 million ten-year Senior Notes due September 19, 2024 | 125,000 | — | 125,000 |
| 4.24% $125 million ten-year Senior Notes due June 25, 2025 | 125,000 | — | 125,000 |
| 3.91% $75 million ten-year Senior Notes due June 25, 2029 | 75,000 | — | 75,000 |
| 3.19% $50 million fifteen-year Senior Notes due January 24, 2035 | 50,000 | — | 50,000 |
| 1.47% Euro 125 million fifteen-year Senior Notes due June 17, 2030 | — | 145,637 | 145,637 |
| 1.30% Euro 135 million fifteen-year Senior Notes due November 6, 2034 | — | 157,288 | 157,288 |
| Debt issuance costs, net | (1,191) | (889) | (2,080) |
| Total Senior Notes | 473,809 | 302,036 | 775,845 |
| $1.1 billion Credit Agreement, interest at LIBOR plus 87.5 basis points | 321,005 | 71,024 | 392,029 |
| Other local arrangements | 1,581 | 54,792 | 56,373 |
| Total debt | 796,395 | 427,852 | 1,224,247 |
| Less: current portion | (374) | (54,737) | (55,111) |
| Total long-term debt | $796,021 | $373,115 | $1,169,136 |

As of September 30, 2020, approximately $700.7 million of additional borrowings was available under our Credit Agreement, and we maintained $153.7 million of cash and cash equivalents. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates. Further, we do not have any downgrade triggers related to ratings from rating agencies that would accelerate the maturity dates of our debt. We were in compliance with our debt covenants at September 30, 2020.

We currently believe that cash flow from operating activities, together with liquidity available under our Credit Agreement and local working capital facilities and our cash balances, will be sufficient to fund currently anticipated working capital needs and capital spending requirements for the foreseeable future.

We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness. During the nine months ended September 30, 2019, we paid $10 million related to the settlement of the Biotix acquisition contingent consideration as further described in Note 4 of our Annual Report on Form 10-K for the year ended December 31, 2019.

In April 2018, two of our non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to a wholly owned subsidiary of the Company. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points. The loans were renewed for one year in April 2020.

#### Share Repurchase Program

In November 2020, the Company's Board of Directors authorized an additional $2.5 billion to be added to our share repurchase program, which has $0.9 billion of remaining availability as of September 30, 2020. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, stock price, trading restrictions, the level of acquisition activity, and other factors.

We have purchased 29.1 million shares since the inception of the program through September 30, 2020. During the nine months ended September 30, 2020 and 2019, we spent $400 million and $558.7 million on the repurchase of 475,530 and 794,603 shares at an average price per share of $841.14 and $703.16, respectively. We also reissued 144,776 shares and 226,841 shares held in treasury upon the exercise of stock options and vesting of restricted stock units during the nine months ended September 30, 2020 and 2019, respectively.

### Effect of Currency on Results of Operations

Our earnings are affected by changes in exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, Chinese renminbi, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings decrease. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also decrease. We estimate a 1% strengthening of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.

We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese renminbi. The impact on our earnings before tax of the Chinese renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.8 million to $2.0 million annually.

In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on our outstanding debt at September 30, 2020, we estimate that a 5% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $22.6 million in the reported U.S. dollar value of our debt.

### Forward-Looking Statements Disclaimer

*You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties, including statements about expected revenue growth and long-term impacts of the COVID-19 pandemic. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue.”*

*We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, customer demand, our competitive position, pricing, our supply chain, adequacy of our facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, planned research and development efforts and product introductions, capital expenditures, cash flow, tax-related matters, the impact of foreign currencies, compliance with laws, effects of acquisitions, and the impact of the COVID-19 pandemic on our businesses.*

*Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including the uncertain duration and severity of the COVID-19 pandemic. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the SEC from time to time.*

## Market risk

As filed, 178 characters.

As of September 30, 2020, there was no material change in the information provided under Item 7A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

## Controls and procedures

As filed, 708 characters.

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer, have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,694 characters.

For the three and nine months ended September 30, 2020 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except the following update.

*The COVID-19 outbreak has and will likely continue to negatively affect various aspects of our business, including our workforce and supply chain, and make it more difficult and expensive to meet our obligations to our customers, and has and will likely continue to result in reduced demand from our customers as their businesses may also be negatively affected.*

Our global operations are susceptible to global events that could have an adverse effect on our business results and financial condition.

For instance, we are susceptible to a widespread outbreak of an illness or other health issue, such as the ongoing 2019 Coronavirus outbreak ("COVID-19"), and which now has since spread globally, resulting in millions of confirmed cases throughout the world and in all countries where we conduct business. The outbreak has caused many governments to implement stay-at-home orders, quarantines and significant restrictions on travel. Several governments have also implemented work restrictions that prohibit many employees from going to their customary work locations and which require these employees to work remotely if possible. The quarantines, travel bans, work and other restrictions were initially put in place on a national level in China in January 2020, and with the global spread of the virus, subsequently adopted in many other countries and regions throughout the first half of 2020 with many restrictions commencing in Asia Pacific, Europe, North America and South America. These restrictions continue to change as COVID-19 evolves in each country and region.

As a result of pandemic outbreaks, including COVID-19, businesses can be shut down, supply chains can be interrupted, slowed, or rendered inoperable, and individuals can become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. COVID-19 interferes with general commercial activity related to our supply chain and customer base. In addition, it is expected that COVID-19 will negatively affect the global economy and our customers' businesses, which will result in delayed or reduced purchases from us. Some customers may also have difficulty meeting their payment obligations to us, resulting in late payments or an inability of some customers to make payments at all.

During the nine months ended September 30, 2020, COVID-19 had a negative impact on our business, primarily related to reduced global customer demand. We remain cautious as uncertainties related to COVID-19 and the resulting impact to the economy continues in all regions of the world and market conditions may also change quickly. With the global spread of the virus and related negative impact to the global economy, we may experience reduced global sales volume from lower customer demand in future quarters. Our operations could be negatively affected further if our employees who are currently not subject to stay-at-home or work restriction orders are quarantined or become ill as a result of exposure to COVID-19, or if they become subject to governmental COVID-19 curfews or stay-at-home orders. The longer-term effects on our business will be impacted by the global economy and any recession implications in different regions of the world. While it is extremely difficult to estimate the extent and duration of any COVID-19 implications, the effects on our business, results of operations and financial condition could be material.

Filed Nov 6, 2020.
Source: SEC EDGAR, the filing index for accession 0001037646-20-000030. Last ingested by Listed: Nov 13, 2026, 02:43 ET. No prices; not investment advice.
